JOP20220104A1 - Dosing regimen for anti-dll3 agents - Google Patents

Dosing regimen for anti-dll3 agents

Info

Publication number
JOP20220104A1
JOP20220104A1 JOP/2022/0104A JOP20220104A JOP20220104A1 JO P20220104 A1 JOP20220104 A1 JO P20220104A1 JO P20220104 A JOP20220104 A JO P20220104A JO P20220104 A1 JOP20220104 A1 JO P20220104A1
Authority
JO
Jordan
Prior art keywords
dll3
agents
dosing regimen
sclc
agent
Prior art date
Application number
JOP/2022/0104A
Other languages
Arabic (ar)
Inventor
Vijay Upreti
Marie-Anne Damiette Smit
Neelesh Soman
Aditya Shetty
Michael Liao
Mukul Minocha
Gataree Ngarmchamnanrith
Sadraei Nooshin Hashemi
Marc Anthony Yago
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of JOP20220104A1 publication Critical patent/JOP20220104A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3023—Lung
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)

Abstract

يتعلق الاختراع الحالي بتوفير طريقة لمعالجة سرطان موجب DLL3 أو SCLC، تشمل إعطاء خاضع بحاجة إليها عامل مضاد لـ DLL3 بجرعة بين حوالي 0.3 مجم إلى حوالي 100 مجم أو بين حوالي 3 مجم إلى حوالي 200 مجم، مرة واحدة كل أسبوعين. يتم أيضاً الكشف عن التجريع التدريجي للعامل المضاد لـ DLL3 لمعالجة SCLC.The present invention relates to providing a method for the treatment of DLL3-positive cancer or SCLC, comprising the administration of a subject who needs it an anti-DLL3 agent at a dose of between about 0.3 mg to about 100 mg or between about 3 mg to about 200 mg, once every two weeks. Stepwise dosing of an anti-DLL3 agent for the treatment of SCLC is also being investigated.

JOP/2022/0104A 2019-11-10 2022-05-09 Dosing regimen for anti-dll3 agents JOP20220104A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19208214.7A EP3819312A1 (en) 2019-11-10 2019-11-10 Dosing regimen for anti-dll3 agents
US202063078131P 2020-09-14 2020-09-14
PCT/US2020/059052 WO2021092134A1 (en) 2019-11-10 2020-11-05 Dosing regimen for anti-dll3 agents

Publications (1)

Publication Number Publication Date
JOP20220104A1 true JOP20220104A1 (en) 2023-01-30

Family

ID=68531385

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2022/0104A JOP20220104A1 (en) 2019-11-10 2022-05-09 Dosing regimen for anti-dll3 agents

Country Status (15)

Country Link
US (1) US20230174643A1 (en)
EP (2) EP3819312A1 (en)
JP (2) JP7709434B2 (en)
KR (1) KR20220097470A (en)
CN (2) CN120053637A (en)
AR (1) AR120399A1 (en)
AU (1) AU2020377981A1 (en)
CA (1) CA3156229A1 (en)
IL (1) IL292463A (en)
JO (1) JOP20220104A1 (en)
MX (1) MX2022005596A (en)
TN (1) TN2022000113A1 (en)
TW (1) TWI908743B (en)
UY (1) UY38948A (en)
WO (1) WO2021092134A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240153575A (en) * 2022-02-23 2024-10-23 암젠 인크 Cancer treatments targeting DLL3
EP4712977A1 (en) * 2023-05-19 2026-03-25 Boehringer Ingelheim International GmbH Uses of t cell engaging proteins in the treatment of cancer
CN121909211A (en) * 2023-09-21 2026-04-21 乐普生物科技股份有限公司 Anti-DLL 3 antibodies and uses thereof
TW202600599A (en) * 2024-03-11 2026-01-01 大陸商樂普生物科技股份有限公司 Anti-dll3 antibodies and uses thereof
TW202602488A (en) 2024-03-11 2026-01-16 美商安進公司 Method of treating brain metastases in subjects with a dll3-positive cancer
WO2026060304A1 (en) 2024-09-13 2026-03-19 Amgen Inc. Subcutaneous administration of anti-dll3 agent for treatment of cancer
WO2026075950A1 (en) 2024-10-01 2026-04-09 Amgen Inc. Dosing regimen for anti-dll3 agent
CN120168667B (en) * 2025-03-18 2026-04-14 中国科学院近代物理研究所 Application of polypeptide in preparation of specific targeting molecular probe for tumor over-expressed by DLL3

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7112324B1 (en) 1998-04-21 2006-09-26 Micromet Ag CD 19×CD3 specific polypeptides and uses thereof
MXPA06004035A (en) 2003-10-16 2006-08-31 Micromet Ag Multispecific deimmunized cd3-binders.
RS53008B2 (en) 2007-04-03 2022-12-30 Amgen Res Munich Gmbh Cross-species-specific cd3-epsilon binding domain
BR112014020826A8 (en) * 2012-02-24 2017-09-19 Stem Centrx Inc ANTIBODY SPECIFICALLY BINDING TO AN Epitope, NUCLEIC ACID, VECTOR OR HOST CELL, DRUG CONJUGATE ANTIBODY, PHARMACEUTICAL COMPOSITION COMPRISING SAID ANTIBODY, USE THEREOF, KIT AND METHOD OF PREPARATION OF THE CONJUGATE
GB201302447D0 (en) * 2013-02-12 2013-03-27 Oxford Biotherapeutics Ltd Therapeutic and diagnostic target
TWI793062B (en) * 2015-07-31 2023-02-21 德商安美基研究（慕尼黑）公司 Antibody constructs for dll3 and cd3
MX2018002166A (en) * 2015-08-20 2018-09-12 Abbvie Stemcentrx Llc Anti-dll3 antibody drug conjugates and methods of use.
IL319047A (en) * 2015-08-28 2025-04-01 Amunix Operating Inc Chimeric polypeptide assembly and methods of making and using the same
HRP20260151T1 (en) * 2016-08-02 2026-03-27 Visterra, Inc. MODIFIED POLYPEPTIDES AND THEIR USE
WO2018107116A1 (en) * 2016-12-09 2018-06-14 Abbvie Stemcentrx Llc Methods of reducing toxicity of antibody drug conjugates, and compositions produced thereby
UY37726A (en) * 2017-05-05 2018-11-30 Amgen Inc PHARMACEUTICAL COMPOSITION THAT INCLUDES BISPECTIFIC ANTIBODY CONSTRUCTIONS FOR IMPROVED STORAGE AND ADMINISTRATION

Also Published As

Publication number Publication date
WO2021092134A1 (en) 2021-05-14
US20230174643A1 (en) 2023-06-08
EP4054636A1 (en) 2022-09-14
JP2023501375A (en) 2023-01-18
KR20220097470A (en) 2022-07-07
IL292463A (en) 2022-06-01
AU2020377981A1 (en) 2022-05-26
TWI908743B (en) 2025-12-21
UY38948A (en) 2021-05-31
CN120053637A (en) 2025-05-30
AR120399A1 (en) 2022-02-09
CN114746117A (en) 2022-07-12
CA3156229A1 (en) 2021-05-14
TN2022000113A1 (en) 2024-01-02
JP2025148407A (en) 2025-10-07
EP4054636A4 (en) 2024-01-03
JP7709434B2 (en) 2025-07-16
EP3819312A1 (en) 2021-05-12
CN114746117B (en) 2025-02-28
TW202128762A (en) 2021-08-01
MX2022005596A (en) 2022-05-20

Similar Documents

Publication Publication Date Title
JOP20220104A1 (en) Dosing regimen for anti-dll3 agents
NZ775660A (en) Combination therapy including a krasg12c inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers
MX393855B (en) COMBINATION THERAPY INCLUDING A RAF INHIBITOR AND TRAMETINIB
MA39726A (en) PHARMACEUTICAL COMPOSITIONS OF THERAPEUTICALLY ACTIVE COMPOUNDS
NZ764953A (en) Use of a vegf antagonist to treat angiogenic eye disorders
MA47313B1 (en) Her2 antibody subcutaneous formulations
MA39725B1 (en) Pharmaceutical compositions of therapeutically active compounds
MA39094A1 (en) Combination therapy comprising an inhibitor of mdm2 and one or more additional pharmaceutically active principles for the treatment of cancers
EA201691454A1 (en) COMPOSITIONS OF PRIDOPIDININE MODIFIED SHIPPING
ZA202103820B (en) Capsule formulations
EA201990424A1 (en) SPIRALACTAM MODULERS OF NMDA RECEPTOR AND THEIR APPLICATION
PH12020500099A1 (en) Therapeutic combination of a third generation egfr tyrosine kinase inhibitor and a cyclin d kinase inhibitor
EA201990428A1 (en) SPIRALACTAM MODULERS OF NMDA RECEPTOR AND THEIR APPLICATION
MA39765A (en) Pharmaceutical formulations of a pan-raf kinase inhibitor, processes for their preparation, and methods of use
PH12020500096A1 (en) Therapeutic combination of a third generation egfr tyrosine kinase inhibitor and a raf inhibitor
CL2017001756A1 (en) Dosing regimen for madcam antagonists.
ZA202000028B (en) Use of vibegron to treat overactive bladder
MA42301B1 (en) CRYSTALLINE SALT OF (S)-[3,4-DIFLOORO-2-(2-FLUORO-4-IODOPHENYLAMINO)PHENYL][3-HYDROXY-3-(PIPERIDIN-2-YL)AZETIDIN-1-YL]-METHANONE FUMARATE
MX2023000187A (en) DOSAGE OF VIBEGRON FOR THE TREATMENT OF OVERACTIVE BLADDER.
AR119159A1 (en) ANGIOEDEMA TREATMENTS
MX2021007330A (en) Therapeutic methods and compositions for treating cancer using 6,8-bis-benzylthio-octanoic acid and an autophagy inhibitor.
CO2021014370A2 (en) Dosage regimens for anti-RSV antibodies and compositions that include them
JOP20250015A1 (en) Pharmaceutical formulation of antibodies against CD20 and their uses
EA202191415A1 (en) COMBINATION THERAPY INCLUDING KRASG12C INHIBITOR AND ONE OR MORE ADDITIONAL PHARMACEUTICALLY ACTIVE AGENTS FOR TREATING KINDS OF CANCER
EA202090416A1 (en) METHODS FOR TREATING GASTROPARESIS SYMPTOMS USING A VELUSETRAGA